“Head and Neck Atopic Dermatitis: Therapeutic Response After Switching to Upadacitinib in Moderate-to-Severe Atopic Dermatitis Patients Who Had Inadequate Response to Dupilumab”, J of Skin, vol. 10, no. 2, p. s740, Mar. 2026, doi: 10.25251/ztj3rn69.